NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that seven major research-based medical centers in New York City, including Rockefeller University, NYU Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College, have joined Pfizer’s Centers for Therapeutic Innovation, a network of partnerships that aims to speed the translatio

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 5:00 p.m., New York City time on Friday, January 28, 2011, un

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 5:00 p.m., New York City time on Friday, January 28, 2011, un

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011. “This action represents a significant step in

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011. “This action represents a significant step in

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qu

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care and Oncology, at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 3:00 p.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “29th Annual J.P. Morgan Healthcare Conference” link in the Investor Presentations sec

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Animal Health today announced the completion of its acquisition of Synbiotics Corporation (Pinksheets SYNB.PK) on December 30, 2010, resulting in the cessation of trading of Synbiotics common stock. Shareholders of record of Synbiotics’ common stock will receive written instructions, including a letter of transmittal, for exchanging their Synbiotics common stock for the merger consideration. Holders in "street" name should contact their broker to receive th